Wave life sciences reports second quarter 2022 financial results and provides business update

Wve-006 announced as investigational development candidate for aatd with cta submissions expected in 2023;  first-in-class rna editing candidate and most advanced program currently in development using an oligonucleotide to harness an endogenous enzyme for editing
WVE Ratings Summary
WVE Quant Ranking